Document is current

Any future updates will be listed below

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12885-016-2301-6

Published Online: 2016-04-09

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark